Key facts
- It has raised $57.4M; the latest was Later Stage VC in Aug 2024.
- Notable investors include Cedar Mundi Ventures, Research Corporation Technologies.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for AustinPx
- ·The full record, as it builds
Funding rounds
No funding rounds for AustinPx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AustinPx
Operator of a contract development and manufacturing organization intended for analytical and formulation development services and cGMP manufacturing for small molecule drugs. The company offers preclinical services through Phase II formulation and process development and GMP manufacturing of oral dosage forms, enabling healthcare providers to focus on creating novel therapeutics from poorly bioavailable drugs to deliver clinical benefits to patients.
- Sector
- Healthcare
- HQ
- Georgetown, TX, United States
- Founded
- 2007
- Employees
- 61
- Website
- austinpx.com/
- Ownership
- Privately Held (backing)
AustinPx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AustinPx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AustinPx in its N-PORT filings yet. We sweep new filings monthly.